Vivaldi Biosciences AG

Founded

2014

Staff

3

Organization type

RDM biotech/pharma

Region

Vienna

Vivaldi AG was formed to rapidly advance the clinical development of a new-generation influenza vaccine to address the urgent, unmet need for a safer and more effective pediatric influenza vaccine. deltaFLU is based on a novel method of attenuation and unique mode of action of that confer cross-reactivity and cross-protection against variant influenza strains, key attributes of a long-sought universal influenza vaccine, which has the potential to transform the influenza vaccine market.

R&D:deltaFLU has been evaluated in Phase 1 and 2 clinical studies, demonstrating safety, immunogenicity, cross-reactivity, and showing that the deltaFLU vaccine viruses are replication-deficient and non-shedding. Vivaldi is pursuing manufacturing process development, scale-up, and GMP manufacturing of clinical trial material through a partner with expertise in these fields. Vivaldi plans to undertake Phase 2 clinical trials of its deltaFLU candidate in paediatric subjects.